This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

MLex Comment: J&J may seek EC scrutiny for rumoured Synthes purchase

By Sille Ruubel ( April 18, 2011, 16:03 GMT | Comment) -- US healthcare group Johnson & Johnson’s rumoured acquisition of Swiss medical-device maker Synthes would be likely to require European Commission merger-control approval, given their respective revenues in Europe. Regulatory scrutiny may focus on potential overlaps in the manufacturing of implants and instruments used to treat traumatic and spinal injuries.US healthcare group Johnson & Johnson’s (J&J) rumoured acquisition of Swiss medical-device maker Synthes would be likely to require European Commission merger-control approval....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login